Peptide Database

Peptide NameMERS-CoV-HR2P-GSGSGC

Function Ontology

Anticancer ▸ Cytotoxic anticancer activity ▸ Cytotoxic

Antimicrobial

Antiviral

Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV

Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV-2

Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition

Enzyme modulation ▸ Enzyme inhibition ▸ Infection inhibition

Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor

Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic

Venom / Toxin ▸ General toxin ▸ Cytotoxic

Standard StatusStandard

Sequence Length42 amino acids

Chemical FormulaC200H331N49O69S2

DescriptionStandard

        SLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKELGSGSGC
    

Molecular Weight4590.18 Da

Isoelectric Point (pI)4.18

Net Charge (pH 7.0)-3.54

Net Charge (pH 7.4) -3.78

Charge Density (pH 7.0) -0.0844

GRAVY Index0.10

Hydrophobic Moment 0.61

Boman Index0.14

Instability Index16.58

Aliphatic Index 118.33

Aromaticity 0.0476

Extinction Coeff. Reduced 2980.00

Extinction Coeff. Oxidized 2980.00

The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.

Amino Acid Composition

TPSA 1932.94

LogP -20.58

H-bond Donors 67.0

H-bond Acceptors 68.0

Rotatable Bonds 158.0

Heavy Atoms 320.0

Ring Count 2.0

Amide Bonds 46.0

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.

2D CHEMICAL STRUCTURE

Drag to move

Drag to move. Use the buttons to zoom.

RECORD: Rec_0074130 VERIFIED: YES

Provenance & Taxonomy

Organismsynthetic construct [Synthetic]

FamilyHR2 fusion-inhibitory peptide

Tax ID32630

Structure & Mods

Configlinear peptide [Linear]

Chiralitycanonical L-amino-acid peptide [L]

N-TermNone

C-TermNone

Bio-Activity Profile

Function

Antiviral Anti-MERS-CoV Fusion inhibition

TargetMERS-CoV | 293T cells

Activity0.417±0.18 μM

MethodIC50

Half-LifeMammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h

PaperInhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. | Outlaw VK, Bovier FT, Mears MC, Cajimat MN, Zhu Y, Lin MJ, Addetia A, Lieberman NAP, Peddu V, Xie X, Shi PY, Greninger AL, Gellman SH, Bente DA, Moscona A, Porotto M. | mBio. 2020 Oct 20;11(5):e01935-20. | DOI:10.1128/mBio.01935-20 | PMID:33082259 PMID33082259 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/33082259/

RECORD: Rec_0075147 VERIFIED: YES

Provenance & Taxonomy

Organismsynthetic construct [Synthetic]

Tax ID32630

Structure & Mods

Configlinear peptide [Linear]

Chiralitycanonical L-amino-acid peptide [L]

N-TermNone

C-TermNone

Bio-Activity Profile

Function

Antimicrobial Anti-SARS-CoV-2 Cytotoxic

RECORD: Rec_0087061 VERIFIED: YES

Provenance & Taxonomy

Organismsynthetic construct [Synthetic]

FamilyHR2 fusion-inhibitory peptide

Tax ID32630

Structure & Mods

Configlinear peptide [Linear]

Chiralitycanonical L-amino-acid peptide [L]

N-TermNone

C-TermNone

Bio-Activity Profile

Function

Antiviral Anti-SARS-CoV-2 Fusion inhibition

TargetSARS-CoV-2_S247R | 293T cells

Activity1 μM

MethodIC90

Half-LifeMammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h

PaperInhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. | Outlaw VK, Bovier FT, Mears MC, Cajimat MN, Zhu Y, Lin MJ, Addetia A, Lieberman NAP, Peddu V, Xie X, Shi PY, Greninger AL, Gellman SH, Bente DA, Moscona A, Porotto M. | mBio. 2020 Oct 20;11(5):e01935-20. | DOI:10.1128/mBio.01935-20 | PMID:33082259 PMID33082259 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/33082259/

RECORD: Rec_0162087 VERIFIED: YES

Provenance & Taxonomy

Organismsynthetic construct [Synthetic]

FamilyHR2 fusion-inhibitory peptide

Tax ID32630

Structure & Mods

Configlinear peptide [Linear]

Chiralitycanonical L-amino-acid peptide [L]

N-TermNone

C-TermNone

Bio-Activity Profile

Function

Antiviral Anti-SARS-CoV Fusion inhibition

TargetSARS-CoV-1 | 293T cells

Activity0.7 μM

MethodIC90

Half-LifeMammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h

PaperInhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. | Outlaw VK, Bovier FT, Mears MC, Cajimat MN, Zhu Y, Lin MJ, Addetia A, Lieberman NAP, Peddu V, Xie X, Shi PY, Greninger AL, Gellman SH, Bente DA, Moscona A, Porotto M. | mBio. 2020 Oct 20;11(5):e01935-20. | DOI:10.1128/mBio.01935-20 | PMID:33082259 PMID33082259 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/33082259/

RECORD: Rec_0172216 VERIFIED: YES

Provenance & Taxonomy

Organismsynthetic construct [Synthetic]

FamilyHR2 fusion-inhibitory peptide

Tax ID32630

Structure & Mods

Configlinear peptide [Linear]

Chiralitycanonical L-amino-acid peptide [L]

N-TermNone

C-TermNone

Bio-Activity Profile

Function

Antiviral Anti-SARS-CoV-2 Fusion inhibition

TargetSARS-CoV-2_D614G | 293T cells

Activity1 μM

MethodIC90

Half-LifeMammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h

PaperInhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. | Outlaw VK, Bovier FT, Mears MC, Cajimat MN, Zhu Y, Lin MJ, Addetia A, Lieberman NAP, Peddu V, Xie X, Shi PY, Greninger AL, Gellman SH, Bente DA, Moscona A, Porotto M. | mBio. 2020 Oct 20;11(5):e01935-20. | DOI:10.1128/mBio.01935-20 | PMID:33082259 PMID33082259 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/33082259/

FIRST PREV 1 2 3 4 5 NEXT LAST

Showing 5 records on this page Ã‚Â· Page 2 of 5